Advagen Pharma Europe OÜRegistered
Annual reports for 2024, 2025 not filed.
Key figures
354 702 €
Revenue 2023
Ratios
20231,9%
Profit margin
0,3%
Equity ratio
1,0×
Current ratio
100,0%
Return on equity
Balance sheet structure
Current assetsNon-current assetsLiabilitiesEquity
Quarterly figures
| Quarter | Revenue | Number of employees | Labour taxes |
|---|---|---|---|
| Q2 2026 | 0 € | — | — |
| Q1 2026 | 0 € | — | — |
| Q4 2025 | 0 € | — | — |
| Q3 2025 | 0 € | — | — |
| Q2 2025 | 0 € | — | — |
| Q1 2025 | 0 € | — | 0 € |
Source: Tax Board open data — based on VAT returns, may not exactly match revenue in the annual report. Updated quarterly.
Summary of financial statements2023
| 2023 | |
|---|---|
| Balance sheet — assets | |
| Total current assets | 2 226 759 |
| Total non-current assets | — |
| Total assets | 2 226 759 |
| Balance sheet — liabilities and equity | |
| Current liabilities | 2 220 044 |
| Non-current liabilities | — |
| Total liabilities | 2 220 044 |
| Share capital | 0 |
| Retained earnings of previous periods | — |
| Profit for the year | 6715 |
| Total equity | 6715 |
| Income statement | |
| Sales revenue | 354 702 |
| Operating profit | 11 135 |
| Profit before income tax | 6715 |
| Profit for the reporting year | 6715 |
| Labour costs | 0 |
| Depreciation of non-current assets | — |
| Other indicators | |
| Employees | 0 |
| Calculated dividend | — |
A dash (—) means the report has not been filed or the line is not reported; 0 is a zero stated in the report.
Connections graph
CompanyPersonShareholderOther roleAdditional link
Annual reportsPDF, XBRL
Loading list of reports…
Source: e-Business Register (RIK). Files open/download directly from the official register.
Related companies
Same activity — Ravimpreparaatide tootmine